A review and update on melanocyte stimulating hormone therapy: afamelanotide
- PMID: 23884489
A review and update on melanocyte stimulating hormone therapy: afamelanotide
Abstract
Afamelanotide ([Nle4-D-Phe7]-alpha-MSH) is an analog of alpha-melanocyte stimulating hormone given as a subcutaneous injection. Afamelanotide is currently undergoing phase II and III trials in Europe and the US for skin diseases including vitiligo, erythropoietic protoporphyria, polymorphic light eruption and prevention of actinic keratoses in organ transplant recipients. Unregulated analogs and chemicals are being sold online ahead of formal approval. A number of counterfeit chemicals, 'Melanotans' are being sold for tanning purposes. Currently, afamelanotide is already on the market in Italy and Switzerland for patients with erythropoietic protoporphyria. This paper will review the current literature on this promising compound.
Similar articles
-
Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.Expert Opin Investig Drugs. 2010 Dec;19(12):1591-602. doi: 10.1517/13543784.2010.535515. Epub 2010 Nov 13. Expert Opin Investig Drugs. 2010. PMID: 21073357 Review.
-
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria.Expert Rev Clin Pharmacol. 2015 Jan;8(1):43-53. doi: 10.1586/17512433.2014.956089. Epub 2014 Dec 3. Expert Rev Clin Pharmacol. 2015. PMID: 25470471 Review.
-
Alpha-melanocyte stimulating hormone analogues: the perils and the promise.J Drugs Dermatol. 2009 Aug;8(8):772-6. J Drugs Dermatol. 2009. PMID: 19663117 Review. No abstract available.
-
Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.Photochem Photobiol. 2009 Nov-Dec;85(6):1434-9. doi: 10.1111/j.1751-1097.2009.00595.x. Photochem Photobiol. 2009. PMID: 19656325 Clinical Trial.
-
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.Clin Pharmacokinet. 2017 Aug;56(8):815-823. doi: 10.1007/s40262-016-0501-5. Clin Pharmacokinet. 2017. PMID: 28063031 Review.
Cited by
-
MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.Pigment Cell Melanoma Res. 2014 Sep;27(5):699-720. doi: 10.1111/pcmr.12257. Epub 2014 May 30. Pigment Cell Melanoma Res. 2014. PMID: 24807163 Free PMC article. Review.
-
Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.Photochem Photobiol Sci. 2021 Feb;20(2):315-320. doi: 10.1007/s43630-021-00020-2. Epub 2021 Feb 17. Photochem Photobiol Sci. 2021. PMID: 33721252
-
Advances in the management of erythropoietic protoporphyria - role of afamelanotide.Appl Clin Genet. 2016 Dec 12;9:179-189. doi: 10.2147/TACG.S122030. eCollection 2016. Appl Clin Genet. 2016. PMID: 28003770 Free PMC article. Review.
-
Scopoletin from Cirsium setidens Increases Melanin Synthesis via CREB Phosphorylation in B16F10 Cells.Korean J Physiol Pharmacol. 2014 Aug;18(4):307-11. doi: 10.4196/kjpp.2014.18.4.307. Epub 2014 Aug 13. Korean J Physiol Pharmacol. 2014. PMID: 25177162 Free PMC article.
-
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel). 2020 Mar 5;13(3):40. doi: 10.3390/ph13030040. Pharmaceuticals (Basel). 2020. PMID: 32151051 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
